Sulfasalazine(SJS)

## Report on Sulfasalazine Adverse Drug Reaction Labeling Requirements **1. Executive Summary:** This report analyzes a communication from the Drugs Controller General India (DCGI) regarding Sulfasalazine. The document details a directive to include Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) as adverse drug reactions in the label, package insert, and promotional literature of Sulfasalazine formulations marketed in India. This directive arises from recommendations by the Pharmacovigilance Programme of India (PvPI) and the Subject Expert Committee (SEC) following the evaluation of adverse drug reaction reports. The key finding is the mandated change in labeling requirements for Sulfasalazine to enhance patient safety through improved awareness of potential adverse reactions. **2. Introduction:** This report aims to provide information regarding a directive issued by the Drugs Controller General India (DCGI) concerning the labeling requirements for Sulfasalazine formulations in India, based solely on the provided policy text. **3. Policy Overview:** This is an **amendment** to existing regulations, mandating a specific change in the labeling of Sulfasalazine. * **Core Objective(s):** * Enhance patient safety. * Improve awareness of potential adverse drug reactions associated with Sulfasalazine. * Incorporate recommendations from the Pharmacovigilance Programme of India (PvPI). **4. Background and Rationale:** This amendment addresses a perceived need to highlight the risk of Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) associated with Sulfasalazine. The rationale stems from ADR reports and subsequent evaluation by the PvPI and SEC, indicating a need for improved communication of these risks to healthcare professionals and patients. The provided text suggests that previous labeling did not adequately address these specific adverse reactions, hence the directive for inclusion. **5. Key Provisions / Changes:** * **Specific Part of the Original Policy Being Changed:** While the original policy isn't provided, this amendment mandates a specific alteration to the existing labeling requirements for Sulfasalazine. * **New Rule/Provision:** Manufacturers of Sulfasalazine formulations are required to mention Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) as adverse drug reactions in the label, package insert, and promotional literature of the drug. * **Difference/Effect of this Change:** The change ensures that healthcare professionals and patients are explicitly informed about the potential risk of SJS and TEN associated with Sulfasalazine use. This is expected to lead to increased vigilance, earlier detection of these reactions, and potentially improved patient outcomes. The new provision directly adds explicit warnings to product labeling. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders are: * **Manufacturers of Sulfasalazine formulations in India:** They are directly responsible for implementing the labeling changes. * **State/UT Drugs Controllers:** They are responsible for directing and overseeing manufacturers within their jurisdiction to comply with the directive. * **Healthcare professionals (prescribers, pharmacists):** They need to be aware of this new labeling information to inform patients and manage potential adverse reactions. * **Patients taking Sulfasalazine:** They are the ultimate beneficiaries, gaining improved access to information about potential risks. **7. Implementation Aspects (Inferred):** * **Responsible agency/bodies:** * Drugs Controller General India (DCGI) is responsible for issuing the directive. * Central Drugs Standard Control Organization (CDSCO) is involved in the process. * State/UT Drugs Controllers are responsible for implementation and oversight at the state level. * **Timelines or procedures:** The text requests the State/UT Drugs Controllers to intimate the office on action taken in this regard, suggesting a follow-up mechanism is in place. There is no specified timeframe, but the request for intimation implies an expectation of prompt action. * The amendment specifically relies on existing state-level drug control bodies to enforce the change. **8. Expected Outcomes / Impact of Changes:** The intended outcome of these changes is to: * Increase awareness among healthcare professionals and patients about the potential risk of SJS and TEN associated with Sulfasalazine. * Facilitate earlier detection and management of these adverse reactions. * Ultimately improve patient safety by enabling informed decision-making and timely intervention. * The impact is a heightened vigilance around Sulfasalazine usage. **9. Conclusion:** The directive from the DCGI mandates the inclusion of SJS and TEN as adverse drug reactions in Sulfasalazine labeling, package inserts, and promotional literature. This amendment, driven by recommendations from the PvPI and SEC, aims to enhance patient safety through improved awareness of potential risks. Manufacturers of Sulfasalazine formulations are directly affected and must implement these changes under the supervision of State/UT Drugs Controllers. This amendment reinforces the importance of ongoing pharmacovigilance and adaptation of drug labeling to reflect evolving safety information.

Key Entities Referenced